menu
    • menu
    [{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ASN008","moa":"NaV Channel","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Asana BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"TrialSpark","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ASN008","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"TrialSpark","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"TrialSpark \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TrialSpark \/ Not Applicable"},{"orgOrder":0,"company":"Formation Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2024","type":"Series D Financing","leadProduct":"ASN008","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Formation Bio","amount2":0.37,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.37,"dosageForm":"Gel","sponsorNew":"Formation Bio \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Formation Bio \/ Sanofi"}]

    Find Clinical Drug Pipeline Developments & Deals for ASN008

    Menu

    ASN008

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Formation Bio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Formation Bio

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASN008

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Sanofi

                            Deal Size : $372.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            Formation Bio Raises Series D to Expand Drug Pipeline and AI-Driven Development Platform

                            Details : The fund aims to advance the pipeline, which includes the company lead product ASN008, a sodium channel blocker. Currently, it is being evaluated for the treatment of atopic dermatitis.

                            Brand Name : ASN008

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 26, 2024

                            Lead Product(s) : ASN008

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Sanofi

                            Deal Size : $372.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TrialSpark

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            TrialSpark

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASN008

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TrialSpark Announces First Patient Dosed in Phase 2 Clinical Trial for ASN008-201 in Atopic Dermatitis

                            Details : ASN008, a Phase 2-ready topical sodium channel blocker in development for atopic dermatitis. ASN008 has shown promising efficacy data in pruritus (itch) associated with atopic dermatitis.

                            Brand Name : ASN008

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 23, 2023

                            Lead Product(s) : ASN008

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Asana BioSciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Asana BioSciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASN008

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Asana BioSciences Announce ASN008 Achieves Positive Results

                            Details : The results showed that a single application of ASN008 achieved a clinically meaningful reduction in pruritus of ? 4 points on the NRS in 2-3 hours.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 10, 2020

                            Lead Product(s) : ASN008

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth